OrthoPediatrics Corp.
NASDAQ:KIDSMedical - Devices
+$0.19 today
- Market cap
- $826.40M
- Beta
- 1.01
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$1.68
Volume 0.16M
Average 0.16M
KIDS EBITDA Margin
EBITDA as a percentage of revenue.
OrthoPediatrics Corp.NASDAQ: KIDS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -5.1%
EBITDA Margin was -5.1% in Q1 FY2026, up 3.1 pp from a year earlier. On a trailing-twelve-month basis it was -2.7%, up 3.5 pp year over year. Over 3 fiscal years it widened by 2.1 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -1.2% for the fiscal year ending Dec 2026, up from -5.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -5.1%-8.3 pp QoQ
- Last fiscal yearDec 2025
- -5.1%+4.8 pp YoY
- LTMMar 2026
- -2.7%+3.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.1 pp | +2.6 pp | -0.4 pp |
| 1 year | +4.8 pp | +3.9 pp | -0.9 pp |
| 3 years | +2.1 pp | +11.6 pp | +9.6 pp |
| 5 years | +19.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5.1%
- Year-over-year change
- +4.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5.1% | +4.8pp |
| FY2024 | 2024-12-31 | -9.9% | -4.2pp |
| FY2023 | 2023-12-31 | -5.6% | +1.5pp |
| FY2022 | 2022-12-31 | -7.1% | +0.2pp |
| FY2021 | 2021-12-31 | -7.3% | — |
EBITDA Margin vs competitors
How KIDS compares with its peers on the latest reported figures
- KIDS's LTM Mar 2026 EBITDA Margin of -2.7% is the 2nd highest of the 8 companies compared; the peer median is -22.3%.
- Its year-over-year change of +3.5 pp is the 4th highest of 8, against a peer median of -2.1 pp.
- Over three fiscal years its change of +2.1 pp compares with a peer median of +41.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 17.9% | +11.6 pp | +41.2 pp | |
| LTM Mar 2026 | -2.7% | +3.5 pp | +2.1 pp | |
| LTM Mar 2026 | -4.6% | +6.2 pp | +28.7 pp | |
| LTM Mar 2026 | -5.4% | +6.2 pp | +18.3 pp | |
| LTM Mar 2026 | -22.3% | -4.0 pp | +5.3 pp | |
| LTM Mar 2026 | -33.9% | -19.3 pp | +89.0 pp | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -60.2% | -2.1 pp | +78.9 pp |
| LTM Mar 2026 | -94.5% | -30.2 pp | +72.1 pp | |
| Peer median (excluding KIDS) | -22.3% | -2.1 pp | +41.2 pp | |
Competitors are the stored peer set for KIDS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 98.05M | 122.29M | 148.73M | 204.73M | 236.35M |
| Cost of Revenue | 24.65M | 31.63M | 37.48M | 56.13M | 63.69M |
| Gross Profit | 73.4M | 90.66M | 111.25M | 148.6M | 172.66M |
| Gross Margin | 74.9% | 74.1% | 74.8% | 72.6% | 73.1% |
| Research & Development | 5.54M | 8.45M | 10.9M | 11.03M | 9.1M |
| Selling, General & Admin | 85.73M | 104M | 126.12M | 167.09M | 192.56M |
| Operating Expenses | 91.43M | 116.06M | 138M | 178.12M | 201.66M |
| Depreciation & Amortization | 10.68M | 13.1M | 17.39M | 19.08M | 21.25M |
| EBITDA | (7.19M) | (8.69M) | (8.38M) | (20.23M) | (11.94M) |
| EBITDA Margin | -7.3% | -7.1% | -5.6% | -9.9% | -5.1% |
| Operating Income | (18.02M) | (25.4M) | (26.75M) | (29.52M) | (29M) |
| Operating Margin | -18.4% | -20.8% | -18.0% | -14.4% | -12.3% |
| Interest Income | 0 | 0 | 198K | 0 | 0 |
| Interest Expense | 2.25M | 2.42M | 0 | 2.62M | 6M |
| Other Income / Expenses | 636K | 21.71M | 5.44M | (12.41M) | (10.19M) |
| Income Before Tax | (17.39M) | (3.69M) | (21.31M) | (41.93M) | (39.19M) |
| Pre-Tax Margin | -17.7% | -3.0% | -14.3% | -20.5% | -16.6% |
| Income Tax Expense | (1.13M) | (4.95M) | (338K) | (4.11M) | 460K |
| Net Income | (16.26M) | 1.26M | (20.97M) | (37.82M) | (39.65M) |
| Net Margin | -16.6% | 1.0% | -14.1% | -18.5% | -16.8% |
| EPS (Basic) | (0.84) | 0.06 | (0.92) | (1.64) | (1.69) |
| EPS (Diluted) | (0.84) | 0.06 | (0.92) | (1.64) | (1.69) |
| Weighted Avg Shares | 19.27M | 20.7M | 22.68M | 23.08M | 23.46M |
| Weighted Avg Shares (Diluted) | 19.27M | 20.95M | 22.68M | 23.08M | 23.46M |
OrthoPediatrics Corp.
NASDAQ:KIDS
Intrinsic Alpha fair value
Locked
Current Price
$31.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.